Interleukin-1β inhibitors for the management of acute gout flares: a systematic literature review
Authors' conclusion
IL-1β inhibitors may be a beneficial and safe medication for patients experiencing gout flares for whom current standard therapies are unsuitable.
Study context
- Population
- Adult patients experiencing gout flares; studies published 2011–202214 studies (10 RCTs)
- Participants
- 4,367 patients
- Comparison
- IL-1β inhibitors vs comparators
- Outcome
- Pain resolution (RCTs)
Methodological detailsnarrative synthesis, Cochrane Risk of Bias Tool 2 for RCTs and Downs and Black for non-RCTs, two independent reviewers
- Narrative synthesis
- Cochrane Risk of Bias Tool 2 for RCTs and Downs and Black for non-RCTs
- Two independent reviewers
Pooled result
As reported in the abstract
- Canakinumab and rilonacept: better response than active comparator for resolving pain
- Anakinra: appeared not inferior to active comparator for resolving pain
Further pooled results
- Canakinumab and rilonacept reduced frequency of gout flares vs comparators
Safety
Tolerability
- All three medications mostly well-tolerated vs comparators
Original publication
Interleukin-1β inhibitors for the management of acute gout flares: a systematic literature review. Arthritis Res Ther. Published 25 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →